Payers have great expectations for real world data. Is pharma meeting them?
It's sink or swim time. Advancements in drug data collection methodologies and deeper understanding of what can be achieved has finally opened the floodgates on real world data (RWD). Information is coming onstream thick and fast and pharma can either become disoriented or use it to drive forward harder-hitting payer strategies. But what do payers in the US and Europe actually want to see before they dive into this exciting opportunity?
From payer liaison to data analysts to senior strategists—this report ensures everyone involved understands exactly what payers want today. Access senior payer views, in their own words, on all the key issues.
Use this report to:
What to expect from this report
Yes, you have an RWD strategy and of course you're talking to payers all the time—but how much detailed insight do you have that joins these two together? This report bridges the gap, giving a timely and valuable look at what payers are thinking about RWD at this point, as well as a host of new ideas on how to help them utilise RWD more positively.
Real World Data and Evidence: Payer Insights provides exactly what you need to refine your RWD strategy for payers and achieve better results in the long term.
How did we do it?
Example insight included in Real World Data and Evidence: Payer Insights
"Payers want to overcome the variety and complexity of RWD; pharma companies can assist by facilitating the development of standardised clinical data recording methods and formalisation of data capabilities in payer organisations. Payers require assistance in harnessing insights from real-world information. Hence, they value pharma's efforts to improve the reliability and credibility of RWD, which includes the endorsement of data standardisation and harmonisation initiatives to promote integrity, authenticity and confidentiality of electronic health records. Pharma can provide payers with support, sponsorship, and training in the effective use of RWD to refine their clinical and economic assessments and ensure therapies reach the right patients."
Example quote included in Real World Data and Evidence: Payer Insights
"RWE is underutilised in supporting discussions around formulary position, management and restrictions during negotiations. RWE would strengthen the case for positioning of medicines in formulary positions."
The expert panel for Real World Data and Evidence: Payer Insights
Why buy now?
RWD and RWE provision has reached a tipping point. Heightened levels of interest and a desire to end reliance on clinical trial data alone has created the ideal market conditions for pharma to move forward. But success is dependent on addressing lingering concerns about data quality, complexity and usability and moving into new territory. This report offers a timely insight into the payer mindset and reveals lots of ways in which pharma can better work with payers to achieve the mutual benefits offered by effective RWD provision.
Why FirstWord reports are different
All Contents Copyright © 2021 Doctor's Guide Publishing Limited All Rights Reserved